Skip to content

Mepolizumab and in-office nasal polypectomy in patients with chronic rhinosinusitis (CRS). A three arm study.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-505426-34-01
Acronym
MELYSA
Enrollment
75
Registered
2023-10-20
Start date
2023-12-18
Completion date
Unknown
Last updated
2025-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic rhinosinusitis (CRS)

Brief summary

SINO-NASAL OUTCOME TEST (SNOT-22)

Detailed description

VAS score for nasal symptoms, The following measurement will be assessed using a nasopharyngoscope: 1. CRSwNP: Lund-Kennedy scale 2. CRSwNP: Meltzer scale, Need of rescue therapy with systemic corticosteroids: dose, route of administration, length of treatment, number of treatments., Need of rescue surgery (either in-office polypectomy or full endoscopic sinus surgery), The resected polyp in the polypectomy groups will be sent for histology to confirm that it is eosinophilic and to obtain evidence of type 2 inflammation (tissue eos> 10/hpf), The safety of the treatment will be assessed by collecting Adverse Events at each of the study visits.

Interventions

Sponsors

Instituto De Investigacion Marques De Valdecilla
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
SINO-NASAL OUTCOME TEST (SNOT-22)

Secondary

MeasureTime frame
VAS score for nasal symptoms, The following measurement will be assessed using a nasopharyngoscope: 1. CRSwNP: Lund-Kennedy scale 2. CRSwNP: Meltzer scale, Need of rescue therapy with systemic corticosteroids: dose, route of administration, length of treatment, number of treatments., Need of rescue surgery (either in-office polypectomy or full endoscopic sinus surgery), The resected polyp in the polypectomy groups will be sent for histology to confirm that it is eosinophilic and to obtain evidence of type 2 inflammation (tissue eos> 10/hpf), The safety of the treatment will be assessed by collecting Adverse Events at each of the study visits.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026